|Awarded On||June 18, 2010|
|Title||Cancer Biology and Genetics Including Oncogenesis Genomics and Proteomics|
|Program||Product Development Research|
|Award Mechanism||Company Commercialization|
|Principal Investigator/Program Director||James Mapes|
|Cancer Sites||Multiple Sites|
Rules-Based Medicine® (RBM), the world’s leading multiplexed biomarker testing laboratory, provides comprehensive protein biomarker products and services based on its Multi-Analyte Profiling (MAP) technology platform. RBM’s biomarker testing service provides pre-clinical and clinical researchers with reproducible, quantitative, multiplexed immunoassay data for hundreds of proteins in a cost-effective manner, from a small sample volume and from multiple species. RBM is CLIA certified and supports GLP studies.
Most diseases and drug effects manifest themselves in abnormal levels of specific biomarkers found in the peripheral blood. By providing multiplexed, quantitative, and reproducible te...